Answers are grounded in this paper and cite their sources.
Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission. This case emphasises that management with the targeted immunomodulatory agent dupilumab, which has minimal adverse impact on ICI efficacy, can be effective for cirAEs, including steroid‐refractory PL‐like eruptions, and may allow for continuation of ICI treatment.
No takes yet. Share an insight, caveat, or question.
Christou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: